ReviewFrontiers in oncology2025
Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncology research · 2026Review
- Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer continues to pose a considerable global health challenge, especially in low- and middle-income nations, although progress in screening and vaccine efforts. In recent years, immunotherapy has emerged as a promising treatment option; nevertheless, its efficacy in cervical cancer is constrained by the intricate and heterogeneous tumor immune microenvironment. Reliable biomarkers to predict which patients will benefit from immunotherapy are lacking. The heterogeneity of the immune landscape across patients adds further complexity. This paper offers a thorough examination of the immunological landscape in cervical cancer, highlighting the interactions among tumor cells, immune infiltrates, and stromal elements. Moreover, we investigate how advanced technologies-such as single-cell RNA sequencing, spatial transcriptomics, and multiplex imaging-are transforming our comprehension of immunological heterogeneity and uncovering new therapeutic targets. We seek to delineate present problems and potential pathways in the development of effective, tailored immunotherapies for cervical cancer by integrating genetic analysis with immunological insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.